Fraser Finance

The Landbanking Group is a private, social-benefit company that unites scientists, builders, technology experts, and investors to enhance investments in natural capital. It operates an eco-tech platform designed to facilitate payments and investments related to ecosystem services. Through its platform, the company offers account documentation and trade certificates that verify ecosystem outcomes, thereby creating market access across various natural markets. This innovative approach enables both investors and businesses to establish natural capital accounts, promoting sustainable practices and investments in environmental resources.

Therapixel SA is a company based in Valbonne, France, with additional locations across multiple countries, including Australia and China. Founded in 2013, Therapixel specializes in designing and developing medical image analytics software for surgeons, leveraging artificial intelligence to enhance surgical procedures. Their product portfolio includes Radvise, an automatic image reading solution; Fluid, a touchless medical image navigation system for surgery; Anywhere, a post-processing workstation; and CD-Feed, a solution for importing CDs from outpatient imaging exams. The company also focuses on AI-based software for breast cancer detection and characterization, providing healthcare professionals with pertinent information to support decision-making during surgeries while adhering to sterility constraints.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Incision is a developer of a medical education platform designed to provide a standardized approach to performing medical procedures through a series of practical steps and sub-steps. The platform facilitates access to shared experiences, skills, and expertise, enabling medical students to achieve rapid and thorough preparation for their roles in the operating room. By focusing on the development of essential competencies and skills, Incision aims to enhance the training of future healthcare professionals.

Spearad GmbH is a technology company based in Frankfurt am Main, Germany, specializing in addressable television advertising. Founded in 2019, it operates a multi-format platform that enables media owners, including broadcasters and OTT providers, to effectively monetize content across various screens. The platform offers a suite of tools for media planning, central campaign management, and real-time reporting, facilitating targeted advertising campaigns. Additionally, Spearad provides a demand-side platform that grants broadcasters access to an ad marketplace, allowing for flexible ad breaks and monetization strategies. With a focus on integrating digital advertising capabilities into traditional television and audio formats, Spearad aims to transform the advertising landscape while enhancing revenue opportunities for its clients. The company also has subsidiaries in the UK and the US, reflecting its commitment to operating on a global scale.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Tessian Limited is a company that specializes in email security software designed to mitigate risks associated with human error and data loss. Founded in 2013 and headquartered in London, the company offers advanced solutions that leverage machine learning and artificial intelligence. Key products include CheckRecipient Guardian, which alerts users in real-time if emails are being sent to unintended recipients, and CheckRecipient RuleBuilder, which allows organizations to easily create and enforce email communication policies. The platform analyzes email networks to prevent sensitive information from being misdirected, thereby protecting clients in various sectors, including legal services, healthcare, investment banking, and technology. Tessian aims to enhance security while ensuring minimal disruption to employees' workflows, empowering them to work efficiently without compromising data integrity.

Clinical Genomics Pty Ltd. is a biotechnology company focused on developing and marketing innovative diagnostic products for colorectal cancer (CRC). Founded in 2006 and headquartered in North Ryde, Australia, with additional offices in New Jersey and Sydney, the company offers solutions such as Colvera, a blood-based circulating tumor DNA test designed to monitor CRC recurrence by detecting methylated DNA from the BCAT1 and IKZF1 genes. Additionally, it provides InSure FIT, a fecal immunochemical test that identifies blood in stool samples. Clinical Genomics has established a strategic alliance with Quest Diagnostics and boasts a robust intellectual property portfolio with over 20 patents. The company aims to enhance CRC screening and monitoring through its advanced testing solutions.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

ExThera Medical Corporation is a medical device company based in Martinez, California, with an additional office in Stockholm, Sweden. Founded in 2007, the company focuses on addressing unmet clinical needs in the treatment of bloodstream infections and pathogen reduction in blood banking. Its flagship product, the Seraph Microbind Affinity Blood Filter, is designed to capture and remove a wide range of pathogens, including normal and drug-resistant bacteria, viruses, toxins, and pro-inflammatory cytokines from human blood. The device utilizes the affinity of bacteria for immobilized heparin, a naturally occurring anticoagulant, to lower pathogen concentration in the bloodstream. This innovative approach serves as an adjunct to conventional anti-infective therapies, potentially reducing the load and duration of infections and helping patients recover by supporting their immune systems. ExThera Medical's solutions aim to improve clinical outcomes for patients suffering from blood-borne diseases, including viremia and bacteremia, and enhance the safety of banked human blood.

Tessian Limited is a company that specializes in email security software designed to mitigate risks associated with human error and data loss. Founded in 2013 and headquartered in London, the company offers advanced solutions that leverage machine learning and artificial intelligence. Key products include CheckRecipient Guardian, which alerts users in real-time if emails are being sent to unintended recipients, and CheckRecipient RuleBuilder, which allows organizations to easily create and enforce email communication policies. The platform analyzes email networks to prevent sensitive information from being misdirected, thereby protecting clients in various sectors, including legal services, healthcare, investment banking, and technology. Tessian aims to enhance security while ensuring minimal disruption to employees' workflows, empowering them to work efficiently without compromising data integrity.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Pole Star, established in 2002 and operating in the United States and France, is a leading provider of indoor location technology. The company specializes in delivering high-performance indoor location services, geofencing, and analytics solutions that allow users to navigate and locate assets and individuals within various environments, including buildings, airports, malls, and convention centers. With coverage extending over 100 million square feet of indoor space worldwide, Pole Star aims to facilitate seamless navigation for venue owners and mobile solution providers, ensuring scalability and ease of implementation for its advanced 3D systems.